首页> 美国卫生研究院文献>Drug Design Development and Therapy >Pooled post hoc analysis of population pharmacokinetics of oxycodone and acetaminophen following a single oral dose of biphasic immediate-release/extended-release oxycodone/acetaminophen tablets
【2h】

Pooled post hoc analysis of population pharmacokinetics of oxycodone and acetaminophen following a single oral dose of biphasic immediate-release/extended-release oxycodone/acetaminophen tablets

机译:口服口服双相立即释放/延长释放羟考酮/对乙酰氨基酚片后对羟考酮和对乙酰氨基酚的群体药代动力学进行事后分析汇总

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This analysis evaluated the single-dose population pharmacokinetics (PK) of biphasic immediate-release (IR)/extended-release (ER) oxycodone (OC)/acetaminophen (APAP) 7.5/325 mg tablets administered under fasted conditions and the effects of a meal on their single-dose population PK. Data were pooled from four randomized, single-dose crossover trials enrolling healthy adult (18–55 years old) participants (three trials) and nondependent recreational users of prescription opioids (one trial) with a body weight of ≥59 kg. Participants received IR/ER OC/APAP 7.5/325 mg tablets in single doses of 7.5/325 mg (one tablet), 15/650 mg (two tablets), or 30/1,300 mg (four tablets) under fasted or fed conditions. Six variables were examined: sex, race, age, weight, height, and body mass index. Single-dose population PK was analyzed using first-order conditional estimation methods. A total of 151 participants were included in the analysis under fasted conditions, and 31 participants were included in the fed analysis. Under fasted conditions, a 10% change in body weight was accompanied by ~7.5% change in total body clearance (CL/F) and volume of distribution (V/F) of OC and APAP. Black participants had 17.3% lower CL/F and a 16.9% lower V/F of OC compared with white participants. Under fed conditions, the absorption rate constant of OC and APAP decreased significantly, although there was no effect on CL/F and V/F. Considering that the recommended dose for IR/ER OC/APAP 7.5/325 mg tablets is two tablets every 12 hours, adjustments of <50% are not clinically relevant. Dose adjustment may be necessary for large deviations from average body weight, but the small PK effects associated with race and consumption of a meal are not clinically relevant.
机译:该分析评估了在禁食条件下服用的双相立即释放(IR)/延长释放(ER)羟考酮(OC)/对乙酰氨基酚(APAP)7.5 / 325 mg片剂的单剂量人群药代动力学(PK)进餐对其单剂量人群PK。数据来自四项随机,单剂量交叉试验,这些试验招募了健康成人(18-55岁)参与者(三项试验)和体重≥59kg的处方阿片类药物的非依赖性休闲使用者(一项试验)。参与者在禁食或进食条件下分别接受7.5 / 325 mg(一片),15/650 mg(两片)或30 / 1,300 mg(四片)的单剂量IR / ER OC / APAP 7.5 / 325 mg片。检查了六个变量:性别,种族,年龄,体重,身高和体重指数。使用一阶条件估计方法分析单剂量人群PK。禁食条件下的分析总共包括151名参与者,而进食分析中包括31名参与者。在禁食的情况下,OC和APAP的体重变化10%伴随着全身清除率(CL / F)和分布体积(V / F)约〜7.5%的变化。与白人相比,黑人参与者的CL / F降低了17.3%,OC的V / F降低了16.9%。在进食条件下,OC和APAP的吸收速率常数显着降低,尽管对CL / F和V / F没有影响。考虑到IR / ER OC / APAP 7.5 / 325 mg片剂的建议剂量是每12小时2片,因此<50%的调整与临床无关。对于与平均体重的较大偏差,可能需要调整剂量,但是与种族和进餐有关的较小PK效应在临床上不相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号